Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

CD27 enhances the killing effect of CAR T cells targeting trophoblast cell surface antigen 2 in the treatment of solid tumors

(2021) Huanpeng Chen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

(2021) A. Bardia et al.   ANNALS OF ONCOLOGY

Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development

(2021) Manar Hammood et al.   Pharmaceuticals

Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?

(2020) Olga Bednova et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Antibody–Drug Conjugates for Cancer Therapy

(2020) Umbreen Hafeez et al.   MOLECULES

Targeting Topoisomerase I in the Era of Precision Medicine

(2019) Anish Thomas et al.   CLINICAL CANCER RESEARCH

Stable Isotope Dilution LC-HRMS Assay To Determine Free SN-38, Total SN-38, and SN-38G in a Tumor Xenograft Model after Intravenous Administration of Antibody–Drug Conjugate (Sacituzumab Govitecan)

(2019) Renu Pandey et al.   ANALYTICAL CHEMISTRY

U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation

(2019) Koji Haratani et al.   JOURNAL OF CLINICAL INVESTIGATION

Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development

(2018) Shalini Andersson et al.   DRUG DISCOVERY TODAY

A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model

(2018) Tomomi Nakayama Iwata et al.   MOLECULAR CANCER THERAPEUTICS

Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design

(2018) Pamela A. Trail et al.   PHARMACOLOGY & THERAPEUTICS

Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer

(2018) Meghdad Abdollahpour-Alitappeh et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys

(2018) Yoko Nagai et al.   XENOBIOTICA

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

(2017) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy

(2017) Jodi A McKenzie et al.   JNCI-Journal of the National Cancer Institute

Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?

(2017) Florentina Kubizek et al.   PROTEIN AND PEPTIDE LETTERS

Tumor-associated calcium signal transducer 2 regulates neovascularization of non-small-cell lung cancer via activating ERK1/2 signaling pathway

(2017) Xiaobin Guo et al.   TUMOR BIOLOGY

Overexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells

(2017) Bin Wu et al.   Experimental and Therapeutic Medicine

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy

(2017) Jodi A McKenzie et al.   JNCI-Journal of the National Cancer Institute

A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187

(2016) Eric X. Chen et al.   INVESTIGATIONAL NEW DRUGS

Binding of Solvent Molecules to a Protein Surface in Binary Mixtures Follows a Competitive Langmuir Model

(2016) Tobias Kulschewski et al.   LANGMUIR

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates

(2016) Heather Donaghy   mAbs

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

(2015) Thomas M. Cardillo et al.   BIOCONJUGATE CHEMISTRY

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

(2015) A. N. Starodub et al.   CLINICAL CANCER RESEARCH

Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)

(2015) R. M. Sharkey et al.   CLINICAL CANCER RESEARCH

Trop2: From development to disease

(2015) Annie R.A. McDougall et al.   DEVELOPMENTAL DYNAMICS

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

(2015) David M. Goldenberg et al.   Oncotarget

Long-Term Stabilization of Maleimide–Thiol Conjugates

(2014) Shaun D. Fontaine et al.   BIOCONJUGATE CHEMISTRY

Expression of Trop2 Cell Surface Glycoprotein in Normal and Tumor Tissues

(2011) Lara P. Stepan et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma

(2010) Hiromi Kobayashi et al.   VIRCHOWS ARCHIV

Trop2: A possible therapeutic target for late stage epithelial carcinomas

(2009) Rafael Cubas et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management

(2009) Alexander Stein et al.   Therapeutic Advances in Medical Oncology